Biochemical recurrence of prostate cancer after radical prostatectomy encompasses a biologically and clinically heterogeneous group of patients. While many men experience an indolent disease course without clinically significant progression, a subset will develop metastatic disease or die from prostate cancer. Contemporary data suggest that approximately 20–30% of patients with biochemical recurrence ultimately experience clinically meaningful progression [1], which underscores the challenge of appropriate selection of patients for treatment intensification in the postoperative setting.
European Urology published a clinical update in Research Highlights on 16 Jan 2026.
The item focuses on Refining Salvage Radiotherapy After Prostatectomy: Positron Emission Tomography–guided Dose Escalation in EMPIRE-2.
Review the original article for the full source wording and details.